20 Acorn Park Drive
Tel: (617) 949-4359
About Omega Therapeutics
Omega Therapeutics is a publicly held, development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that systematically controls every aspect of an organism’s life from cell genesis, to growth and differentiation. The OMEGA platform has identified thousands of novel DNA-sequence-based epigenomic targets within Insulated Genomic Domains (IGDs), referred to as EpiZips™. IGDs represent the three-dimensional, distinct, and evolutionarily conserved architecture of the genome, and are the fundamental structural and functional units of gene control and cell differentiation. They act as the “control room” of biology. The OMEGA platform examines alterations in IGDs leading to aberrant gene expression, a cause of most disease. It then leverages its database of EpiZips to identify appropriate intervention points within the IGDs and rationally designs biologically engineered, modular, and programmable mRNA-encoded epigenetic medicines, called Omega Epigenomic Controllers™, to target EpiZips for Precision Genomic Control™. With its computation- and data-first approach, Omega Therapeutics is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
56 articles about Omega Therapeutics
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine
Omega Therapeutics, Inc. today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.
Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Omega Therapeutics, Inc. today announced that Mahesh Karande , President and Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.
Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
- Strong Balance Sheet to Fund Pipeline of Omega Epigenomic Controllers™ with $122.4 Million in Cash and Cash Equivelents as of June 30, 2021 and additional $141.1 Million in Gross Proceeds from the Initial Public Offering in the Third Quarter 2021
Omega Therapeutics Announces Pricing of Initial Public Offering
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share
Money on the Move: July 7 – 13
7/14/2021More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar
Omega Therapeutics, Inc. today announced the appointment of Luke Beshar to its Board of Directors.
BioSpace Movers & Shakers, May 21
5/21/2021Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Omega Therapeutics Strengthens Board of Directors with Appointment of R&D Veteran Elliott M. Levy, M.D.
Industry R&D Leader Brings Over Two Decades of Senior Leadership Experience at Amgen and Bristol-Myers Squibb joins Omega Therapeutics
Money on the Move: March 24-30
3/31/2021Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing
Additional Capital from Flagship Pioneering, Joined by Invus, Fidelity Management & Research Company, Funds and Accounts Managed by BlackRock, Cowen, and Others
Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.
Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.
Omega Therapeutics Announces the Industry's First Programmable Epigenetic Medicine in Development and 2021 Priorities
OTX-2002 To Be Developed for the Treatment of MYC-Driven Hepatocellular Carcinoma Company is Advancing Candidate Into IND-Enabling Studies, with the Goal of Commencing a Phase 1/2 Clinical Trial Thereafter
Omega Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the field of Epigenomic Programming™ to precisely regulate and control the human genome to treat and cure disease, today announced that Mahesh Karande , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Heal
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.